How many stocks are there of Cellectis?
The current number of stocks of Cellectis is 57.01 M undefined.
Cellectis Stocks 2024
Cellectis Stocks
57.01 M
Ticker
ALCLS.PA
ISIN
FR0010425595
WKN
A0MKPR
In 2024, Cellectis had 57.01 M outstanding stocks, a 0% change from the 57.01 M stocks in the previous year.
The Cellectis Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 57.01 |
| 2028e | 57.01 |
| 2027e | 57.01 |
| 2026e | 57.01 |
| 2025e | 57.01 |
| 2024e | 57.01 |
| 2023 | 57.01 |
| 2022 | 45.55 |
| 2021 | 44.82 |
| 2020 | 42.5 |
| 2019 | 42.44 |
| 2018 | 40.77 |
| 2017 | 35.69 |
| 2016 | 35.27 |
| 2015 | 34.15 |
| 2014 | 26.19 |
| 2013 | 20.65 |
| 2012 | 19.94 |
| 2011 | 12.29 |
| 2010 | 11.65 |
| 2009 | 10.03 |
| 2008 | 9.19 |
| 2007 | 9.19 |
| 2006 | 5.08 |
| 2005 | 5.08 |
| 2004 | 5.08 |
Cellectis shares outstanding FR0010425595 · A0MKPR
The number of shares was Cellectis in 2023 — This indicates how many shares 57.013 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Cellectis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Cellectis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Cellectis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cellectis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 5.08 M Aktien |
| 2005 | 5.08 M Aktien |
| 2006 | 5.08 M Aktien |
| 2007 | 9.19 M Aktien |
| 2008 | 9.19 M Aktien |
| 2009 | 10.03 M Aktien |
| 2010 | 11.65 M Aktien |
| 2011 | 12.29 M Aktien |
| 2012 | 19.94 M Aktien |
| 2013 | 20.65 M Aktien |
| 2014 | 26.19 M Aktien |
| 2015 | 34.15 M Aktien |
| 2016 | 35.27 M Aktien |
| 2017 | 35.69 M Aktien |
| 2018 | 40.77 M Aktien |
| 2019 | 42.44 M Aktien |
| 2020 | 42.5 M Aktien |
| 2021 | 44.82 M Aktien |
| 2022 | 45.55 M Aktien |
| 2023 | 57.01 M Aktien |
| 2024e | 57.01 M Aktien |
| 2025e | 57.01 M Aktien |
| 2026e | 57.01 M Aktien |
| 2027e | 57.01 M Aktien |
| 2028e | 57.01 M Aktien |
| 2029e | 57.01 M Aktien |
Cellectis Aktienanalyse
What does Cellectis do?
Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Cellectis's Shares Outstanding
Cellectis's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Cellectis’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Cellectis’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Cellectis’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Cellectis stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Cellectis are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Cellectis evolved in recent years?
The number of shares of Cellectis has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Cellectis as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Cellectis?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Cellectis pay?
Over the past 12 months, Cellectis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cellectis is expected to pay a dividend of 0 USD.
What is the dividend yield of Cellectis?
The current dividend yield of Cellectis is .
When does Cellectis pay dividends?
Cellectis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Cellectis?
Cellectis paid dividends every year for the past 0 years.
What is the dividend of Cellectis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Cellectis located?
Cellectis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cellectis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cellectis from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.
When did Cellectis pay the last dividend?
The last dividend was paid out on 10/8/2024.
What was the dividend of Cellectis in the year 2023?
In the year 2023, Cellectis distributed 0 USD as dividends.
In which currency does Cellectis pay out the dividend?
The dividends of Cellectis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Cellectis stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Cellectis
Our stock analysis for Cellectis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
